Skip to content

The impact of intraoperative mechanical power during one lung ventilation on the occurrence of postoperative pulmonary complications in patients with lung cancer undergoing lobectomy and the possibility of improving the current model for predicting postoperative pulmonary complications: a cohort study

The impact of intraoperative mechanical power during one lung ventilation on the occurrence of postoperative pulmonary complications in patients with lung cancer undergoing lobectomy and the possibility of improving the current model for predicting postoperative pulmonary complications: a cohort study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062173
Enrollment
Unknown
Registered
2022-07-27
Start date
2022-08-01
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pulmonary complications

Interventions

Case series:None

Sponsors

The affiliated hospital of Southewest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
51 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with space-occupying lesions who underwent VATS lobectomy in our hospital with an operative time exceeding 1 hour were selected. 1. Patients who were informed and agreed to participate in this clinical observation; 2. Aged between 50 and 80 years; 3. No preoperative evidence of tumor metastasis, and no prior relevant surgery or chemotherapy; 4. No significant preoperative cardiopulmonary dysfunction, with essentially normal liver and kidney function; 5. ASA classification <III.

Exclusion criteria

Exclusion criteria: 1. Emergency surgery; 2. Preoperative cardiac function classification >= Grade III, or complicated by severe cardiovascular or cerebrovascular diseases, liver or kidney dysfunction, neurological or psychiatric disorders, dementia, or psychological diseases; 3. Preoperative moderate to severe chronic obstructive pulmonary disease, pulmonary bullae, severe bronchiectasis, silicosis, pleural effusion, empyema, or diseases of the pleura or chest wall; 4. Contraindications to nerve block (severe coagulation dysfunction, spinal deformity, systemic or local infection); 5. Difficult airway or intubation challenges; 6. Patient refusal to participate or investigator judgment that the patient is unsuitable for the clinical trial; 7. COVID-19 infection within the past six months.

Design outcomes

Primary

MeasureTime frame
postoperative pulmonary complications;

Secondary

MeasureTime frame
Plasma inflammatory factor;lung ultrasound score;End-inspiratory lung volume on the ventilated side;hospital stay;30-day mortality;

Countries

China

Contacts

Public ContactZhang Yingying

The affiliated hospital of Southewest Medical University

yingyingzhang917@gmail.com+86 18982796195

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 26, 2026